Search

Your search keyword '"Böll B"' showing total 285 results
Start Over Author "Böll B"
285 results on '"Böll B"'

8. Transplantationsmedizin in der Intensivmedizin

Author

Michels, G., Ruhparwar, A., Pfister, R., Welte, T., Gottlieb, J., Andriopoulos, N., Teschner, S., Burst, V., Mertens, J., Stippel, D., Herter-Sprie, G., Shimabukuro-Vornhagen, A., Böll, B., von Bergwelt-Baildon, M., Theurich, S., Vehreschild, J., Scheid, C., Chemnitz, J., Kochanek, M., Michels, Guido, editor, and Kochanek, Matthias, editor

Published
2017
Full Text
View/download PDF

9. Onkologie

Author

Kochanek, M., Böll, B., Cornely, O., Michels, G., Michels, Guido, editor, and Kochanek, Matthias, editor

Published
2017
Full Text
View/download PDF

10. Infektiologie

Author

Kochanek, M., Böll, B., Vornhagen, A. S., Michels, G., Cornely, O., Fätkenheuer, G., Aurbach, U., Seifert, H., Gutschow, C., Waldschmidt, D., Rybniker, J., Skouras, E., Vehreschild, M. J. G. T., Vehreschild, J. J., Kaase, M., Scheithauer, S., Michels, Guido, editor, and Kochanek, Matthias, editor

Published
2017
Full Text
View/download PDF

12. Beatmungstherapie

Author

Kochanek, M., Böll, B., Shimabukuro-Vornhagen, A., Michels, G., Michels, Guido, editor, and Kochanek, Matthias, editor

Published
2017
Full Text
View/download PDF

13. Entscheidungshilfe bei erweitertem intensivmedizinischem Behandlungsbedarf auf dem Weg zur Organspende: Positionspapier der Sektion Ethik und der Sektion Organspende und -transplantation der Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin (DIVI) unter Mitarbeit der Sektion Ethik der Deutschen Gesellschaft für Internistische Intensivmedizin und Notfallmedizin (DGIIN)

Author

Neitzke, G., Rogge, A., Lücking, K. M., Böll, B., Burchardi, H., Dannenberg, K., Duttge, G., Dutzmann, J., Erchinger, R., Gretenkort, P., Hartog, C., Jöbges, S., Knochel, K., Liebig, M., Meier, S., Michalsen, A., Michels, G., Mohr, M., Nauck, F., Salomon, F., Seidlein, A.-H., Söffker, G., Stopfkuchen, H., and Janssens, U.

Published
2019
Full Text
View/download PDF

14. Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO)

Author

Kochanek, Matthias, Schalk, E., von Bergwelt-Baildon, M., Beutel, G., Buchheidt, D., Hentrich, M., Henze, L., Kiehl, M., Liebregts, T., von Lilienfeld-Toal, M., Classen, A., Mellinghoff, S., Penack, O., Piepel, C., and Böll, B.

Published
2019
Full Text
View/download PDF

19. Ergänzung des Dokumentationsbogens „Therapiebegrenzung“ unter Berücksichtigung eines möglichen Organspendewunsches: Empfehlung der Sektion Ethik sowie der Sektion Organspende und Organtransplantation der Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin (DIVI) unter Mitarbeit der Sektion Ethik der Deutschen Gesellschaft für Internistische Intensivmedizin und Notfallmedizin (DGIIN)

Author

Janssens, U., Lücking, K. M., Böll, B., Burchardi, H., Dannenberg, K., Duttge, G., Erchinger, R., Gretenkort, P., Hartog, C., Jöbges, S., Knochel, K., Liebig, M., Meier, S., Michalsen, A., Michels, G., Mohr, M., Nauck, F., Radke, P., Rogge, A., Salomon, F., Seidlein, A.-H., Stopfkuchen, H., and Neitzke, G.

Published
2019
Full Text
View/download PDF

23. Sepsis

Author

Böll, B., primary, Kochanek, M., additional, and Shimabukuro-Vornhagen, A., additional

Published
2018
Full Text
View/download PDF

25. Dokumentation der Therapiebegrenzung: Empfehlung der Sektion Ethik der Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin (DIVI) unter Mitarbeit der Sektion Ethik der Deutschen Gesellschaft für Internistische Intensivmedizin und Notfallmedizin (DGIIN)

Author

Neitzke, G., Böll, B., Burchardi, H., Dannenberg, K., Duttge, G., Erchinger, R., Gretenkort, P., Hartog, C., Knochel, K., Liebig, M., Michalsen, A., Michels, G., Mohr, M., Nauck, F., Radke, P., Salomon, F., Stopfkuchen, H., and Janssens, U.

Published
2017
Full Text
View/download PDF

29. Infektiologie

Author

Kochanek, M., primary, Böll, B., additional, Vornhagen, A. S., additional, Michels, G., additional, Cornely, O., additional, Fätkenheuer, G., additional, Aurbach, U., additional, Seifert, H., additional, Gutschow, C., additional, Waldschmidt, D., additional, Rybniker, J., additional, Skouras, E., additional, Vehreschild, M. J. G. T., additional, Vehreschild, J. J., additional, Kaase, M., additional, and Scheithauer, S., additional

Published
2016
Full Text
View/download PDF

30. Transplantationsmedizin in der Intensivmedizin

Author

Michels, G., primary, Ruhparwar, A., additional, Pfister, R., additional, Welte, T., additional, Gottlieb, J., additional, Andriopoulos, N., additional, Teschner, S., additional, Burst, V., additional, Mertens, J., additional, Stippel, D., additional, Herter-Sprie, G., additional, Shimabukuro-Vornhagen, A., additional, Böll, B., additional, von Bergwelt-Baildon, M., additional, Theurich, S., additional, Vehreschild, J., additional, Scheid, C., additional, Chemnitz, J., additional, and Kochanek, M., additional

Published
2016
Full Text
View/download PDF

31. Beatmungstherapie

Author

Kochanek, M., primary, Böll, B., additional, Shimabukuro-Vornhagen, A., additional, and Michels, G., additional

Published
2016
Full Text
View/download PDF

32. Onkologie

Author

Kochanek, M., primary, Böll, B., additional, Cornely, O., additional, and Michels, G., additional

Published
2016
Full Text
View/download PDF

40. A quality improvement study on the reduction of central venous catheter-associated bloodstream infections by use of self-disinfecting venous access caps (STERILE)

Author

Cruz-Aguilar, R., Carney, J., Mondaini, V., Vehreschild, M.J.G.T., Griskaitis, M., Salmanton-García, J., Böll, B., Kochanek, M., Seifert, H., Biehl, L.M., Farowski, F., and Publica

Abstract

Background: Contamination of the catheter hub is an important source of central line-associated bloodstream infections (CLABSI); catheter hub caps incorporating a 70% isopropyl alcohol aim are designed to reduce contamination and hence CLABSI rates. Supporting data in high-risk hematological and oncological patients on the clinical effectiveness of this approach are sparse. Methods: We conducted a before-after single center study accompanying the introduction of such caps at our department. Retrospective data from the year prior to the introduction were compared to 1 year of prospective data. Results: The control and antiseptic barrier cap (ABC) groups consisted of 309 and 289 patients presenting a CLABSI rate of 15.28 and 10.38 per 1,000 catheter days (P=.042), respectively. However, after multivariate analysis, ABCs were not identified as a statistically significant independent protective factor for the occurrence of CLABSI (hazard ratio 0.69, P=.120). There was no significant difference between the groups with respect to time to CLABSI (P=.681), nor the proportion of catheters removed due to suspicion of infection (P=.076). Conclusions: The introduction of ABCs in this high-risk population did not significantly alter CLABSI rates.

Published
2021

41. RICarT : Registry for immune-effector and CAR T associated toxicities

Author

Garcia Borrega, J., Heindel, K., Schmid, C., von Tresckow, Bastian, Reinhardt, Christian, Marks, R., Luther, M. L., Ayuk, F., Wichmann, D., Beutel, G., Obstfelder, E., Schnetzke, U., Schub, N., Baldus, C., Subklewe, M., von Bergwelt, M., Viardot, A., Schellongowski, P., and Böll, B.

Subjects
Medizin, ComputingMethodologies_GENERAL
Abstract

Poster-Abstract

Published
2021

42. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study

Author

Azoulay, É., Castro, P., Maamar, A., Metaxa, V., Moraes, A.G. de, Voigt, L., Wallet, F., Klouche, K., Picard, M., Moreau, A.S., Louw, A. van de, Seguin, A., Mokart, D., Chawla, S., Leroy, J., Böll, B., Issa, N., Levy, B., Hemelaar, P., Fernandez, S., Munshi, L., Bauer, P., Schellongowski, P., Joannidis, M., Moreno-Gonzalez, G., Galstian, G., Darmon, M., Valade, S., Azoulay, É., Castro, P., Maamar, A., Metaxa, V., Moraes, A.G. de, Voigt, L., Wallet, F., Klouche, K., Picard, M., Moreau, A.S., Louw, A. van de, Seguin, A., Mokart, D., Chawla, S., Leroy, J., Böll, B., Issa, N., Levy, B., Hemelaar, P., Fernandez, S., Munshi, L., Bauer, P., Schellongowski, P., Joannidis, M., Moreno-Gonzalez, G., Galstian, G., Darmon, M., and Valade, S.

Abstract

Item does not contain fulltext, BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy can induce side-effects such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS), which often require intensive care unit admission. The aim of this study was to describe management of critically ill CAR T-cell recipients in intensive care. METHODS: This international, multicentre, observational cohort study was done in 21 intensive care units in France, Spain, the USA, the UK, Russia, Canada, Germany, and Austria. Eligible patients were aged 18 years or older; had received CAR T-cell therapy in the past 30 days; and had been admitted to intensive care for any reason. Investigators retrospectively included patients admitted between Feb 1, 2018, and Feb 1, 2019, and prospectively included patients admitted between March 1, 2019, and Feb 1, 2020. Demographic, clinical, laboratory, treatment, and outcome data were extracted from medical records. The primary endpoint was 90-day mortality. Factors associated with mortality were identified using a Cox proportional hazard model. FINDINGS: 942 patients received CAR T-cell therapy, of whom 258 (27%) required admission to intensive care and 241 (26%) were included in the analysis. Admission to intensive care was needed within median 4·5 days (IQR 2·0-7·0) of CAR T-cell infusion. 90-day mortality was 22·4% (95% CI 17·1-27·7; 54 deaths). At initial evaluation on admission, isolated cytokine release syndrome was identified in 101 patients (42%), cytokine release syndrome and ICANS in 93 (39%), and isolated ICANS in seven (3%) patients. Grade 3-4 cytokine release syndrome within 1 day of admission to intensive care was found in 50 (25%) of 200 patients and grade 3-4 ICANS in 38 (35%) of 108 patients. Bacterial infection developed in 30 (12%) patients. Life-saving treatments were used in 75 (31%) patients within 24 h of admission to intensive care, primarily vasoactive drugs in 65 (27%) patients. Factors independently associated

Published
2021

43. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance

Author

Koehler, P., Bassetti, M., Chakrabarti, A, Chen, S.C., Colombo, A.L., Hoenigl, M., Klimko, N., Lass-Flörl, C., Oladele, R.O., Vinh, D.C., Zhu, L.P., Böll, B., Bruggemann, R.J.M., Gangneux, J.P., Perfect, J.R., Patterson, T.F., Persigehl, T., Meis, J.F.G.M., Ostrosky-Zeichner, L., White, P.L., Verweij, P.E., Cornely, O.A., Koehler, P., Bassetti, M., Chakrabarti, A, Chen, S.C., Colombo, A.L., Hoenigl, M., Klimko, N., Lass-Flörl, C., Oladele, R.O., Vinh, D.C., Zhu, L.P., Böll, B., Bruggemann, R.J.M., Gangneux, J.P., Perfect, J.R., Patterson, T.F., Persigehl, T., Meis, J.F.G.M., Ostrosky-Zeichner, L., White, P.L., Verweij, P.E., and Cornely, O.A.

Abstract

Item does not contain fulltext, Severe acute respiratory syndrome coronavirus 2 causes direct damage to the airway epithelium, enabling aspergillus invasion. Reports of COVID-19-associated pulmonary aspergillosis have raised concerns about it worsening the disease course of COVID-19 and increasing mortality. Additionally, the first cases of COVID-19-associated pulmonary aspergillosis caused by azole-resistant aspergillus have been reported. This article constitutes a consensus statement on defining and managing COVID-19-associated pulmonary aspergillosis, prepared by experts and endorsed by medical mycology societies. COVID-19-associated pulmonary aspergillosis is proposed to be defined as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. Recommended first-line therapy is either voriconazole or isavuconazole. If azole resistance is a concern, then liposomal amphotericin B is the drug of choice. Our aim is to provide definitions for clinical research and up-to-date recommendations for clinical management of the diagnosis and treatment of COVID-19-associated pulmonary aspergillosis.

Published
2021

46. Erratum zu: Dokumentation der Therapiebegrenzung

Author

Neitzke, G., Böll, B., Burchardi, H., Dannenberg, K., Duttge, G., Erchinger, R., Gretenkort, P., Hartog, C., Knochel, K., Liebig, M., Michalsen, A., Michels, G., Mohr, M., Nauck, F., Radke, P., Salomon, F., Stopfkuchen, H., and Janssens, U.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results